Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Jose F Rojas

Andrew J Murphy

Ka-Man Venus Lai

Gregg S Warshaw

Lynn Macdonald

David M Valenzuela

John R McWhirter

Corey Momont

Chris Schoenherr

Cagan Gurer

Susannah Brydges

Caitlin Montagna

Chia-Jen Siao

Caitlin L Goshert

Jesper Gromada

Brian Zambrowicz

Mark W Sleeman

Susan D Croll

Xiping Cheng

Nicole M Alessandri-Haber

Charleen Hunt

Meghan Drummond Samuelson

Claudia Gonzaga-Jauregui

John Mcwhirter

Robert Breese

Sandra Kleiner

Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.

Humanized IL-15 animals

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized PNPLA3 locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized PNPLA3 locus express a human PNPLA3 protein or a chimeric PNPLA3 protein, fragments of which are from human PNPLA3. Methods are provided for using such non-human animals comprising a humanized PNPLA3 locus to assess in vivo efficacy of human-PNPLA3-targeting reagents such as nuclease agents designed to target human PNPLA3.

Genetically modified mouse with a humanized PNPLA3 gene and methods of use

Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.

Nuclease-mediated DNA assembly

Methods for introducing a scarless targeted genetic modification into a preexisting targeting vector are provided. The methods can use combinations of bacterial homologous recombination (BHR) and in vitro assembly to introduce such targeted genetic modifications into a preexisting targeting vector in a scarless manner.

Methods for scarless introduction of targeted modifications into targeting vectors

This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.

Rodent model of mood disorders

Growing community of inventors

Newburgh, NY, United States of America

Jose F Rojas